Is Semaglutide Safe? NHS Guidance, Trial Evidence and What to Watch For

The trial data behind the NHS safety assessment

When the MHRA licensed semaglutide (Wegovy) for weight management in the UK, its decision was built on the STEP trial programme — a series of randomised controlled studies involving thousands of adults with obesity. STEP 1, published in the New England Journal of Medicine, followed 1,961 participants for 68 weeks. Alongside the weight-loss results (around 15% average reduction at the 2.4mg maintenance dose, which is the final step if you're curious about what the Wegovy doses are in order) the trial systematically captured adverse events, giving regulators detailed data on which side effects appeared, how often, and how severe they typically were.

The picture that emerged is consistent across the STEP studies: semaglutide has a manageable side-effect profile for most people, with gastrointestinal symptoms as the dominant concern. Serious adverse events were uncommon, and the medicine passed the MHRA's benefit-risk threshold for licensing. The NHS medicines page for semaglutide summarises this for patients in plain language, including which effects to expect and which should prompt a call to your GP or 111.

One important context: the trial populations were closely monitored, with regular clinical contact. That level of oversight matters, it is one reason UK prescribers are required to review patients before and during treatment, not simply at the point of first dispensing.

Side effects the NHS evidence flags most clearly

The most common effects are gastrointestinal. Nausea tops the list; vomiting, diarrhoea, constipation, burping and reflux are also frequently reported. These tend to be at their worst when starting treatment or stepping up to a higher dose, and for many people they ease considerably within one to two weeks as the body acclimatises.

Fatigue, headache, dizziness and injection-site redness are also documented. None of these are trivial if they hit hard, but they are not generally medically dangerous. Staying well hydrated matters, particularly if nausea or diarrhoea is significant, dehydration can put strain on the kidneys, especially in people taking other medicines.

Less common effects worth knowing about: gallbladder problems (gallstones can form with rapid weight change; symptoms include sharp upper-abdominal pain, especially after eating), and changes in heart rate. If you notice your pulse feeling unusually fast, mention it to your prescriber at your next check-in.

Semaglutide is not recommended during pregnancy, while breastfeeding, or if you are actively trying to conceive. It is not licensed for anyone under 18. People with a history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, or previous pancreatitis should discuss this carefully with a prescriber before treatment, and if you are wondering whether semaglutide is available through the NHS for your situation, that page covers eligibility criteria and the referral routes in detail. Our full Wegovy page covers the contraindications in more detail.

When to get medical help: pancreatitis and other urgent signs

In January 2026, the MHRA issued a Drug Safety Update reminding healthcare professionals and patients that acute pancreatitis is a known, infrequent but potentially serious side effect of GLP-1 medicines including semaglutide. The signal was not new (it has appeared in prescribing information since licensing) but the update reinforced the importance of recognising it early.

The key symptom to act on is severe, persistent stomach pain that does not ease, especially pain that radiates towards the back, with or without vomiting. Do not wait to see if it passes. Go to A&E or call 999 if the pain is severe; call 111 if you are unsure but concerned. Do not take another dose until you have spoken to a clinician.

Other signs that warrant prompt medical contact rather than waiting:

• Signs of a serious allergic reaction: swelling of the face, lips or throat, difficulty breathing, widespread rash.
• Severe dehydration from vomiting or diarrhoea: not passing urine, feeling faint, very dark urine.
• Sudden changes in vision, particularly if you have diabetes.
• Significant low mood or thoughts of self-harm, report these to your GP or call 116 123 (Samaritans) at any time.

If you experience any side effect you think may be linked to semaglutide, you can report it directly to the MHRA at yellowcard.mhra.gov.uk. Patient reports are taken seriously and contribute to ongoing safety monitoring.

Safety in practice: what supervised prescribing actually changes

Reading a side-effect list on its own can feel alarming. That is a fair reaction, and a useful reminder of why these medicines require a prescription and clinical oversight rather than being available to buy freely, which is also why we explain whether it is safe to buy Wegovy online so you know what to look for in a legitimate provider. The reassuring flip side is that good prescribing practice substantially changes the risk picture.

A prescriber who reviews your full health history before treatment can identify contraindications, flag interactions with other medicines (including oral contraceptives, which may be less well absorbed during early tirzepatide use, a different consideration for semaglutide, but worth raising with any prescriber), and advise on managing early side effects before they become a reason to stop unnecessarily.

At nume, our clinical team includes GPhC-registered Independent Prescribers who review every consultation personally, not software working through a checklist. They discuss your medical history, current medicines and weight-related health before any treatment is approved. If semaglutide is suitable for you, our prescribers walk you through what to expect at each stage of treatment. If you have any questions after starting, our aftercare team is reachable seven days a week.

Semaglutide is not risk-free. No licensed medicine is. What the evidence shows is that, for carefully selected adults with obesity or a weight-related condition, the benefits in clinical trials substantially outweighed the risks, which is precisely why the MHRA licensed it and the NHS recommends it in specific clinical settings. If you are ready to buy semaglutide through a regulated provider, check your eligibility and speak to our prescribers as part of a free consultation if you would like to understand whether it could be right for you.